Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
On April 13, 2021, BD (NYSE: BDX) announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay has been recognized by the WHO as part of the moderate complexity automated NAAT class for TB diagnostics. This assay allows simultaneous detection of the TB bacteria and mutations for resistance to isoniazid (INH) and rifampicin (RIF). BD emphasizes its commitment to combating antimicrobial resistance and improving TB treatment, marking a significant milestone for the product. The BD MAX™ system is already CE marked and available in Europe and beyond.
BD (Becton, Dickinson and Company) (NYSE: BDX) will announce its financial results for Q2 of fiscal year 2021 on May 6, 2021, at approximately 6:00 a.m. ET. The results will be shared via a press release and presentation materials on its investors' website. Following this, a conference call will be held at 8:00 a.m. ET, and can be accessed through a dedicated telephone line. The webcast will be available for replay until May 13, 2021.
BD (Becton, Dickinson and Company) is set to invest $65 million in a new 120,000 square-foot facility in Tucson, Arizona, aimed at enhancing its supply chain capabilities. The facility will serve as a final-stage manufacturing and sterilization center, expected to be operational by mid-2022, and create approximately 40 new jobs. BD's initiative is projected to generate a $122 million economic impact over the next decade, reinforcing the company's commitment to public health and operational efficiency.
On April 1, 2021, BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid antigen test, the BD Veritor™ Plus System, to screen asymptomatic individuals for SARS-CoV-2 through serial testing. This authorization allows testing twice over two to three days, enhancing the detection of COVID-19 and supporting efforts to return to normalcy. The system facilitates testing in various settings like schools and workplaces, addressing public health reporting challenges through a collaboration with ImageMover for efficient data management.
BD (Becton, Dickinson and Company) announces that the FDA has granted emergency use authorization (EUA) for a rapid antigen test capable of detecting SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor™ Plus System test will be available this summer, enabling healthcare providers to distinguish between these viral infections quickly. The test delivers results in about 15 minutes, streamlining the diagnostic process during the flu season. BD currently has over 70,000 active testing systems across multiple healthcare settings.
BD (Becton, Dickinson and Company) has partnered with ImageMover to launch a mobile app that enhances the reporting of SARS-CoV-2 antigen testing results from the BD Veritor™ Plus System. This app aims to simplify data collection at everyday settings like schools and businesses, addressing the challenges of managing test subject demographics and reporting. Available immediately, the ImageMover app provides secure, automated reporting to health authorities, streamlining the process for organizations lacking sophisticated IT infrastructure. The partnership supports BD's innovation in COVID-19 testing solutions.
BD (Becton, Dickinson and Company) has acquired GSL Solutions, Inc., a company specializing in smart medication devices that enhance the security and efficiency of medication storage and compliance. This acquisition aims to bolster BD's medication management capabilities in retail pharmacies and outpatient settings. BD sees this as a strategic move to address growing market demands for automated tracking of medications. GSL's technology includes RFID-based systems that improve operational efficiency and reduce patient wait times. The transaction is expected to be immaterial financially.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced a collaboration with Scanwell Health to develop an at-home rapid test for SARS-CoV-2. This new test will utilize a BD antigen test paired with Scanwell's mobile app, offering step-by-step instructions for sample collection. Users can analyze results using their device's camera, with plans for automated reporting to health agencies. The initiative aims to enhance COVID-19 testing accessibility. BD has played a significant role in the COVID-19 response, providing a range of diagnostic solutions.
BD (Becton, Dickinson and Company) announced its participation in two upcoming virtual investor conferences. The company will present at the Leerink Virtual 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET, and the Raymond James Virtual 42nd Annual Institutional Investors Conference on March 2, 2021, at 8:20 a.m. ET. Interested investors can access live webcasts and replays on the BD corporate website.
BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and Influenza A+B within 2-3 hours. This test is designed to identify variants from the U.K. and South Africa, with 99.9% match to genetic sequences of these variants. The BD SARS-CoV-2/Flu assay operates on the BD MAX™ System, a platform that can analyze hundreds of samples daily. The product is now available in the U.S. and Europe as part of BD's ongoing response to COVID-19.